Milestone Scientific (MLSS) Maxim Group’s 2024 Healthcare Virtual Summit summary
Event summary combining transcript, slides, and related documents.
Maxim Group’s 2024 Healthcare Virtual Summit summary
19 Jan, 2026Key business developments
Secured Medicare reimbursement pricing for technology, enabling private practitioners to receive $325 per procedure in addition to the primary rate.
Initiated commercialization through a partnership with Axial Biologics, leveraging their relationships in New Jersey, Florida, and Texas.
Launched pilot programs in clinics, focusing on building a baseline of committed clinics with minimum annual purchase volumes to establish 2025 revenue.
Expanded sales force with 27 additional representatives via Axial Biologics and added 1099 salespeople.
Continued strong performance in the dental business, with $9M+ in sales and $2.2M net profit last year.
Market opportunity and strategy
Targeting a $2B total addressable market in pain management, with 9M procedures annually, and focusing on Medicare patients in key states.
Pricing strategy set to minimize upfront costs for clinicians, offering devices at $1,000 and consumables at $200–$250 per procedure.
Building a recurring revenue model by requiring minimum annual purchase volumes from clinics.
International expansion efforts ongoing, with Brazil identified as a key future market.
Seeking partnerships with smaller, focused distributors to accelerate adoption and avoid competition for attention.
Technology and clinical impact
CompuFlo system offers objective, computer-controlled needle placement, reducing training time for clinicians from two years to two procedures.
Clinical studies show over 99.9% first-attempt success rate, compared to 17% false positives with traditional methods.
Technology reduces risk of complications such as cerebrospinal fluid leakage, migraines, paralysis, and mortality, especially in thoracic and cervical procedures.
Demonstrated $400–$504 average savings per patient stay and significant reduction in litigation risk.
System improves efficiency, safety, and predictability in both labor/delivery and pain management settings.
Latest events from Milestone Scientific
- Q2 net income turned positive on a $2M NOL sale, with strong e-commerce and margin gains.MLSS
Q2 20241 Feb 2026 - Expanding into the $2B epidural market with patented tech, strong margins, and new Medicare coverage.MLSS
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Q3 revenue up 22% with strong dental growth, regulatory wins, and improved net loss.MLSS
Q3 202413 Jan 2026 - Virtual meeting to elect directors, ratify auditor, and review governance and compensation.MLSS
Proxy Filing1 Dec 2025 - Q2 2025 revenue up 25% year-over-year, led by dental sales, but liquidity risks persist.MLSS
Q2 202523 Nov 2025 - Q3 2025 saw $2.4M revenue, lower expenses, and improved net loss amid ongoing financial risks.MLSS
Q3 202514 Nov 2025 - Shareholders to vote on board elections, share increase, and auditor ratification at the annual meeting.MLSS
Proxy Filing12 Nov 2025 - 2024 net sales fell to $8.6M with a $4.7M net loss, but new funding and approvals support operations.MLSS
Q4 20249 Jun 2025 - Net loss widened to $2.0M in Q1 2025 as higher expenses offset stable revenue.MLSS
Q1 20256 Jun 2025